New SBIR Funding Announced

Syntermed has received another NIH award for a Phase II SBIR grant titled "Myocardial blood flow quantitation with the novel PET F-18 Flurpiridaz imaging tracer." Award number R44HL123069. The funding period is 3/1/16-2/28/18. The product developed from this grant will improve the field of nuclear cardiology by offering optimized relative and absolute quantitation of myocardial perfusion and blood flow for the F-18 flurpiridaz agent.

Search By Tags
No tags yet.

Syntermed, Inc. 333 Sandy Springs Circle NE, Suite 107, Atlanta, GA 30328 | Tel (888) 263-4446 | Fax (888) 216-7511


© 2014 Syntermed Inc. All Rights Reserved.  |  For permission, email                              

Emory Toolbox is a trademark of Emory University. AdreView, Xeleris and GE are trademark of General Electric Company.

ImageGuide is a trademark of the American Society of Nuclear Cardiology



  • Facebook Classic
  • Google+ App Icon
  • Twitter Classic
  • YouTube Basic Black